Stroke is still a major complication of transcatheter aortic valve replacement (TAVR), with a 30-day mortality of 16.7%. Even in the absence of symptoms, most patients (68-93%) have some type of diffusion imaging defect after TAVR implantation. The Sentinel cerebral protection device (CPD) (Boston Scientific) received FDA approval for the capture of emboligenic material that<a href="https://solaci.org/en/2022/09/21/tct-2022-protected-tavr-3/" title="Read more" >...</a>
The presence of small annuli, defined in this registry as < 23 mm diameter or indexed diameter <12 mm/m2 by CT, continues to be one of the greatest challenges of both surgical and endovascular aortic valve treatments. The FRANCE-TAVI Registry looked at 1,195 patients presenting small annuli. 895 (74.9%) received balloon expandable valves (BEV) and<a href="https://solaci.org/en/2022/09/21/tct-2022-france-tavi-registry-small-annuli/" title="Read more" >...</a>
We have reached the end of SOLACI Sessions 44th edition. We have enjoyed 2 days of intense scientific activities with multiple educational symposia, case study discussions, theoretical and practical approaches to issues of interest in interventional cardiology and fruitful knowledge exchange between prestigious colleagues from Paraguay and Latin America. With over 200 registered attendees and<a href="https://solaci.org/en/2022/07/04/thanks-everyone-for-making-part-of-paraguay-solaci-sessions-2022/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) is a therapeutical option for patients with symptomatic severe aortic stenosis. Current guidelines recommend TAVR in patients ≥75 years with intermediate risk. One of the most frequent complications of this procedure is moderate or greater aortic regurgitation (AR) after implantation. Consequently, new valves have been developed to try and reduce<a href="https://solaci.org/en/2022/06/03/new-generation-acurate-neo2/" title="Read more" >...</a>
At present, we are well aware of the rise in mortality caused by severe tricuspid regurgitation (TR). Medical and surgical treatments have turned out to be suboptimal. Hence, endovascular intervention presents as an alternative therapeutic strategy with promising results. The aim of this multicenter, prospective study was to assess the safety and efficacy of the<a href="https://solaci.org/en/2022/05/30/europcr-2022-clasp-tr-study-promising-results-of-endovascular-intervention-of-tricuspid-regurgitation/" title="Read more" >...</a>
Left atrial enlargement with or without atrial fibrillation (AF), absence of valvular degeneration, and heart failure with preserved function have recently been identified as functional atrial mitral regurgitation (MR). This subtype of secondary MR currently appears to be underdiagnosed, and the need for treatment in the general population might be greater than predicted. The aim<a href="https://solaci.org/en/2022/05/30/europcr-2022-the-mitra-tune-registry-3/" title="Read more" >...</a>
Infective Endocarditis (IE) rate after TAVR ranges from 0.7% to 3.4%, depending on the different analyses, and is comparable to that after SAVR. Close to 50% of patients treated with surgery received a prosthetic valve; in TAVR, the figure is lower, possibly due to the characteristics of patients (even though it remains unclear). Researchers looked<a href="https://solaci.org/en/2022/03/04/infective-endocarditis-in-tavr-whats-the-best-treatment/" title="Read more" >...</a>
This last year, new data in structural heart disease gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence. In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The<a href="https://solaci.org/en/2022/01/05/the-most-relevant-of-2021-in-structural-heart-disease/" title="Read more" >...</a>
A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on a vital topic, peripheral vascular disease. Follow us to keep up to date. The Most Read Articles of 2021: Structural Heart Disease 01- Surgeons’ Claim on Low-Risk Patients with Aortic Stenosis Recent<a href="https://solaci.org/en/2021/12/17/the-most-read-articles-of-2021-structural-heart-disease/" title="Read more" >...</a>
Since the latest version to the Valvular Heart Disease Guidelines from the European Society of Cardiology, plenty of evidence has been accumulating, finally leading to this updated version. In this regard, below you will find what has been called “10 commandments” that sum up this new document, to keep you in the loop. The incidence<a href="https://solaci.org/en/2021/11/29/ten-commandments-for-2021-guidelines-on-valvular-heart-disease/" title="Read more" >...</a>